Related Experiment Videos
Pharmacogenomics of HIV
1Berlex Biosciences, 2600 Hilltop Drive, PO Box 4099, CA 94804-0099, USA. Oliver_Ast@berlex.com
Current Opinion in Molecular Therapeutics
|July 22, 2004
Summary
Highly active antiretroviral therapy (HAART) has significantly reduced HIV morbidity and mortality. Advances in pharmacogenomics offer personalized HIV treatment by predicting drug response and optimizing therapy.
Area of Science:
- Virology
- Pharmacology
- Genetics
Background:
- Antiretroviral treatment for HIV infection has advanced significantly due to new assays and genetic technologies.
- Highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality since 1995.
Purpose of the Study:
- To review the mechanisms of drug bioavailability in relation to pharmacogenomics.
- To discuss the impact and clinical benefits of personalized HIV therapy.
Main Methods:
- Utilizing viral load quantification and sequence analysis for understanding HIV pathology and resistance.
- Developing and validating laboratory tests, including genotypic and phenotypic assays, to predict antiviral drug efficacy and resistance.
- Investigating drug/drug interactions and mutation/drug correlations.
Main Results:
- HAART has led to substantial reductions in HIV-related illness and death.
- Pharmacogenomic tools are evolving to predict patient-specific drug responses, influencing efficacy and toxicity.
- New insights into drug bioavailability, drug/drug interactions, and mutation/drug correlations are emerging.
Conclusions:
- Pharmacogenomic and pharmacogenetic tools hold promise for personalized HIV therapy.
- Optimal clinical integration of these tools for HIV management is still under development.
- Personalized approaches can optimize antiviral efficacy and minimize toxicity in HIV treatment.